This will be the first twirla advisory committee. the previously cited crl issues had nothing to do with safety and/or efficacy of the twirla patch- the cited issues were adhesion and the mfg partner's (corium) ability to laser etch the labeling on the patch itself- and whether laser etching could be done without reformulation of the patch ingredients. adhesion issue was resolved thru a comparitive wear study which proved that twirla adhesion is now "non-inferior" to that of xulane (ortho-evra generic)- the only patch currently available on the chc market. Agile funded the integration of the laser etching capability mfg facility and twirla patch required no reformulation as a result of this process. Though slightly higher than that of xulane, because the study was not bmi (body mass) restrictive, twirla PI is within the fda acceptable range- and the lower estrogen dosage has proven to reduce the risk of blood clotting and other severe side effects of xulane.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.